CL2020002017A1 - Composición anticonceptiva con efectos cardiovasculares reducidos. - Google Patents
Composición anticonceptiva con efectos cardiovasculares reducidos.Info
- Publication number
- CL2020002017A1 CL2020002017A1 CL2020002017A CL2020002017A CL2020002017A1 CL 2020002017 A1 CL2020002017 A1 CL 2020002017A1 CL 2020002017 A CL2020002017 A CL 2020002017A CL 2020002017 A CL2020002017 A CL 2020002017A CL 2020002017 A1 CL2020002017 A1 CL 2020002017A1
- Authority
- CL
- Chile
- Prior art keywords
- thromboembolism
- cardiovascular effects
- reduced
- reduced risk
- reduced cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método anticonceptivo con efectos cardiovasculares reducidos, tal como riesgo reducido de tromboembolismo, tal como riesgo reducido de tromboembolismo venoso (TEV) y riesgo reducido de tromboembolismo aórtico (TEA). El método de la invención comprende administrar a un mamífero hembra una cantidad efectiva de un componente estetrol en combinación con un componente progestogénico. El método goza de un perfil favorable para la tromboembolia en comparación con los métodos disponibles actualmente que emplean anticonceptivos de la llamada segunda, tercera o cuarta generación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571 | 2018-02-07 | ||
| EP18160586 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020002017A1 true CL2020002017A1 (es) | 2020-12-04 |
Family
ID=65278388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020002017A CL2020002017A1 (es) | 2018-02-07 | 2020-07-31 | Composición anticonceptiva con efectos cardiovasculares reducidos. |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP4140489A1 (es) |
| JP (2) | JP2021513507A (es) |
| KR (1) | KR20200118464A (es) |
| CN (2) | CN115429806A (es) |
| AU (1) | AU2019219070A1 (es) |
| CA (2) | CA3178181A1 (es) |
| CL (1) | CL2020002017A1 (es) |
| EC (1) | ECSP20054822A (es) |
| GE (1) | GEP20227407B (es) |
| IL (1) | IL276584B1 (es) |
| JO (1) | JOP20200169A1 (es) |
| MA (1) | MA51733A (es) |
| PH (1) | PH12020500601A1 (es) |
| SG (1) | SG11202007163WA (es) |
| UA (1) | UA126746C2 (es) |
| UY (1) | UY38075A (es) |
| WO (1) | WO2019154899A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203009A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| GEP20217243B (en) | 2015-06-18 | 2021-04-26 | Sprl Estetra | Orodispersible dosage unit containing an estetrol component |
| HUE054551T2 (hu) | 2015-06-18 | 2021-09-28 | Estetra Sprl | Ösztetrolt tartalmazó, szájban diszpergálódó tabletta |
| NO3106148T3 (es) | 2015-06-18 | 2018-08-11 | ||
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TW202203935A (zh) * | 2020-04-16 | 2022-02-01 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (en) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Use of estetrol in treatment of respiratory infection diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| CA2448278C (en) * | 2001-05-23 | 2010-06-08 | Christian Franz Holinka | Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| JP2012527413A (ja) * | 2009-05-22 | 2012-11-08 | バイエル ファーマ アクチエンゲゼルシャフト | 少なくとも一つのエストロゲン、及び／又は少なくとも一つゲスターゲン、及び少なくとも一つのプロバイオティック細菌株を含む、経口投与医薬 |
| WO2012055840A1 (en) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| EP3079671B1 (en) * | 2013-12-12 | 2017-10-25 | Donesta Bioscience B.V. | Orally disintegrating solid dosage unit containing an estetrol component |
| JP2018533542A (ja) | 2016-10-28 | 2018-11-15 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 月経困難症および月経痛の管理のための方法 |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 UY UY38075A patent/UY38075A/es unknown
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/en active Pending
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/en active Pending
- 2019-02-07 AU AU2019219070A patent/AU2019219070A1/en active Pending
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 CA CA3089804A patent/CA3089804A1/en active Pending
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/en active Pending
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/en active Search and Examination
- 2019-02-07 IL IL276584A patent/IL276584B1/en unknown
- 2019-02-07 KR KR1020207025456A patent/KR20200118464A/ko not_active Application Discontinuation
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP2024009834A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UY38075A (es) | 2019-10-01 |
| CN111683664A (zh) | 2020-09-18 |
| CN115429806A (zh) | 2022-12-06 |
| AU2019219070A1 (en) | 2020-09-24 |
| CA3089804A1 (en) | 2019-08-15 |
| UA126746C2 (uk) | 2023-01-18 |
| MA51733A (fr) | 2020-12-16 |
| PH12020500601A1 (en) | 2021-05-17 |
| JOP20200169A1 (ar) | 2020-07-07 |
| ECSP20054822A (es) | 2020-12-31 |
| WO2019154899A1 (en) | 2019-08-15 |
| EP4140489A1 (en) | 2023-03-01 |
| CA3178181A1 (en) | 2019-08-15 |
| IL276584B1 (en) | 2024-06-01 |
| JP2021513507A (ja) | 2021-05-27 |
| EP3749327A1 (en) | 2020-12-16 |
| IL276584A (en) | 2020-09-30 |
| GEP20227407B (en) | 2022-08-25 |
| KR20200118464A (ko) | 2020-10-15 |
| JP2024009834A (ja) | 2024-01-23 |
| SG11202007163WA (en) | 2020-08-28 |
| TW202011967A (zh) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002017A1 (es) | Composición anticonceptiva con efectos cardiovasculares reducidos. | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| CO2019000672A2 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| MX2015016038A (es) | Agente terapéutico y método de uso. | |
| CL2017001964A1 (es) | Encapsulado de agentes activos de alta potencia. | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| MX2017009929A (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
| CO2017011046A2 (es) | Prenda absorbente con buen ajuste | |
| AR114357A1 (es) | Composiciones anticonceptivas con efectos cardiovasculares reducidos | |
| ECSP21040508A (es) | Moduladores de la expresión de foxp3 | |
| CR20190026A (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CO2019013940A2 (es) | Métodos para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii | |
| EA201891752A2 (ru) | Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| CL2021003532A1 (es) | Método para estabilizar el ph de una composición acuosa que comprende un fármaco. | |
| EA202091811A1 (ru) | Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы | |
| CO2021012209A2 (es) | Composición para cuidado oral | |
| BR112017016429A2 (pt) | ?vacina, uso de um antígeno de lawsonia intracellularis não vivo, e, método para reduzir o impacto negativo no ganho de peso diário médio (adwg) de um porco associado com infecção subclínica com lawsonia intracellularis? | |
| AR114011A1 (es) | Uso de celiprolol para tratar el síndrome vascular de ehlers-danlos en mujeres durante el embarazo y período de periparto |